AR064878A1 - Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto. - Google Patents
Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto.Info
- Publication number
- AR064878A1 AR064878A1 ARP080100143A ARP080100143A AR064878A1 AR 064878 A1 AR064878 A1 AR 064878A1 AR P080100143 A ARP080100143 A AR P080100143A AR P080100143 A ARP080100143 A AR P080100143A AR 064878 A1 AR064878 A1 AR 064878A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocycloalkyl
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 208000007502 anemia Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 12
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- -1 -NR5R6 Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 abstract 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88471007P | 2007-01-12 | 2007-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064878A1 true AR064878A1 (es) | 2009-04-29 |
Family
ID=39636631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100143A AR064878A1 (es) | 2007-01-12 | 2008-01-11 | Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7608621B2 (enExample) |
| EP (2) | EP2889289B1 (enExample) |
| JP (1) | JP5313925B2 (enExample) |
| KR (1) | KR101458655B1 (enExample) |
| CN (1) | CN101626685B (enExample) |
| AR (1) | AR064878A1 (enExample) |
| AU (1) | AU2008206441B2 (enExample) |
| BR (1) | BRPI0806566A2 (enExample) |
| CA (1) | CA2675252C (enExample) |
| CL (1) | CL2008000066A1 (enExample) |
| DK (1) | DK2124565T3 (enExample) |
| EA (1) | EA017112B1 (enExample) |
| ES (2) | ES2614355T3 (enExample) |
| HR (1) | HRP20150119T1 (enExample) |
| MX (1) | MX2009007548A (enExample) |
| PL (1) | PL2124565T3 (enExample) |
| PT (1) | PT2124565E (enExample) |
| SI (1) | SI2124565T1 (enExample) |
| TW (1) | TW200845991A (enExample) |
| WO (1) | WO2008089052A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR040672A1 (es) * | 2002-07-25 | 2005-04-13 | Glaxo Group Ltd | Forma de dosificacion farmaceutica multicomponenete, cuerpo apropiado para ser utilizado en la misma y procedimiento para prepararla |
| CN101212967A (zh) | 2005-05-10 | 2008-07-02 | 因塞特公司 | 吲哚胺2,3-双加氧酶调节剂及其用法 |
| ITMI20051085A1 (it) * | 2005-06-10 | 2006-12-11 | Acs Dobfar Spa | Metodo di purificazione del cefotetan |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| AU2007265460B2 (en) | 2006-06-26 | 2011-03-03 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| CA2663057C (en) * | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| PT2294066E (pt) | 2008-04-28 | 2014-11-21 | Janssen Pharmaceutica Nv | Benzoimidazoles como inibidores da prolil-hidroxilase |
| CN104042611B (zh) | 2008-07-08 | 2019-05-14 | 因塞特控股公司 | 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑 |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| EP2326179A4 (en) * | 2008-08-25 | 2011-08-17 | Smithkline Beecham Corp | PROLYLHYDROXYLASEHEMMER |
| JP5631741B2 (ja) * | 2008-11-13 | 2014-11-26 | 日本農薬株式会社 | ピラジン誘導体類の製造方法及びその中間体類 |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| DE102009004061A1 (de) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| AR077417A1 (es) * | 2009-07-17 | 2011-08-24 | Japan Tobacco Inc | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina |
| WO2011048611A1 (en) * | 2009-10-07 | 2011-04-28 | Torrent Pharmaceuticals Limited | Novel fused pyridazine derivatives |
| RS54323B1 (sr) * | 2009-10-21 | 2016-02-29 | Daiichi Sankyo Company, Limited | Derivat 5-hidroksipirimidin-4-karboksamida |
| PH12012500788A1 (en) | 2009-11-06 | 2016-07-27 | Aerpio Therapeutics Inc | Compositions and methods for treating colitis |
| WO2011115687A2 (en) * | 2010-03-19 | 2011-09-22 | Northwestern University | Alkylated sp-b peptoid compounds and related lung surfactant compositions |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| US8865748B2 (en) | 2011-06-06 | 2014-10-21 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| BR112014009910B1 (pt) | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica |
| IN2015DN01035A (enExample) | 2012-07-30 | 2015-06-26 | Taisho Pharmaceutical Co Ltd | |
| MY204336A (en) | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| MY174254A (en) | 2013-11-08 | 2020-04-01 | Incyte Holdings Corp | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
| CN114890943A (zh) | 2013-11-15 | 2022-08-12 | 阿克比治疗有限公司 | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途 |
| EP3190104B1 (en) | 2014-09-02 | 2021-10-27 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| CN105130888A (zh) * | 2015-10-09 | 2015-12-09 | 中国药科大学 | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 |
| CA3001065A1 (en) | 2015-10-14 | 2017-04-20 | Xiaoxi WEI | Compositions and methods for reducing ice crystal formation |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| WO2021127273A1 (en) * | 2019-12-20 | 2021-06-24 | Gb004, Inc. | 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections |
| WO2022179967A1 (en) | 2021-02-23 | 2022-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Vadadustat for treating covid-19 in a hospitalized subject |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650960B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| US6972296B2 (en) * | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| DE10059418A1 (de) | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| US20030176317A1 (en) | 2001-12-06 | 2003-09-18 | Volkmar Guenzler-Pukall | Stabilization of hypoxia inducible factor (HIF) alpha |
| US6878709B2 (en) * | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| WO2003088917A2 (en) | 2002-04-19 | 2003-10-30 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| US7718624B2 (en) | 2004-09-01 | 2010-05-18 | Sitkovsky Michail V | Modulation of immune response and inflammation by targeting hypoxia inducible factors |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| JP5390184B2 (ja) * | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| WO2008013838A2 (en) | 2006-07-25 | 2008-01-31 | Cephalon, Inc. | Pyridizinone derivatives |
| US20090011051A1 (en) | 2006-09-28 | 2009-01-08 | Roth Mark B | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds |
| WO2008073292A2 (en) | 2006-12-08 | 2008-06-19 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn) |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
-
2008
- 2008-01-10 TW TW097100936A patent/TW200845991A/zh unknown
- 2008-01-10 CL CL200800066A patent/CL2008000066A1/es unknown
- 2008-01-11 PL PL08727581T patent/PL2124565T3/pl unknown
- 2008-01-11 US US11/972,702 patent/US7608621B2/en not_active Ceased
- 2008-01-11 ES ES14196983.2T patent/ES2614355T3/es active Active
- 2008-01-11 EA EA200970680A patent/EA017112B1/ru not_active IP Right Cessation
- 2008-01-11 EP EP14196983.2A patent/EP2889289B1/en active Active
- 2008-01-11 MX MX2009007548A patent/MX2009007548A/es active IP Right Grant
- 2008-01-11 AU AU2008206441A patent/AU2008206441B2/en not_active Ceased
- 2008-01-11 HR HRP20150119TT patent/HRP20150119T1/hr unknown
- 2008-01-11 BR BRPI0806566-7A patent/BRPI0806566A2/pt not_active IP Right Cessation
- 2008-01-11 DK DK08727581.4T patent/DK2124565T3/en active
- 2008-01-11 CN CN2008800073024A patent/CN101626685B/zh not_active Expired - Fee Related
- 2008-01-11 PT PT08727581T patent/PT2124565E/pt unknown
- 2008-01-11 EP EP08727581.4A patent/EP2124565B1/en active Active
- 2008-01-11 ES ES08727581.4T patent/ES2528745T3/es active Active
- 2008-01-11 CA CA2675252A patent/CA2675252C/en active Active
- 2008-01-11 JP JP2009545699A patent/JP5313925B2/ja active Active
- 2008-01-11 KR KR1020097016748A patent/KR101458655B1/ko active Active
- 2008-01-11 WO PCT/US2008/050833 patent/WO2008089052A2/en not_active Ceased
- 2008-01-11 AR ARP080100143A patent/AR064878A1/es active IP Right Grant
- 2008-01-11 SI SI200831409T patent/SI2124565T1/sl unknown
-
2011
- 2011-10-26 US US13/281,965 patent/USRE44613E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2124565B1 (en) | 2015-01-07 |
| KR20090101376A (ko) | 2009-09-25 |
| JP5313925B2 (ja) | 2013-10-09 |
| MX2009007548A (es) | 2009-07-22 |
| US20080214549A1 (en) | 2008-09-04 |
| USRE44613E1 (en) | 2013-11-26 |
| KR101458655B1 (ko) | 2014-11-05 |
| CN101626685A (zh) | 2010-01-13 |
| BRPI0806566A2 (pt) | 2014-05-06 |
| CL2008000066A1 (es) | 2008-08-01 |
| WO2008089052A3 (en) | 2008-09-18 |
| AU2008206441B2 (en) | 2014-06-19 |
| EP2124565A2 (en) | 2009-12-02 |
| EP2124565A4 (en) | 2011-06-29 |
| EA200970680A1 (ru) | 2010-02-26 |
| EA017112B1 (ru) | 2012-09-28 |
| CA2675252A1 (en) | 2008-07-24 |
| EP2889289A1 (en) | 2015-07-01 |
| CN101626685B (zh) | 2013-03-13 |
| PL2124565T3 (pl) | 2015-05-29 |
| JP2010515756A (ja) | 2010-05-13 |
| CA2675252C (en) | 2015-05-26 |
| EP2889289B1 (en) | 2016-12-21 |
| US7608621B2 (en) | 2009-10-27 |
| ES2614355T3 (es) | 2017-05-30 |
| PT2124565E (pt) | 2015-03-26 |
| SI2124565T1 (sl) | 2015-04-30 |
| DK2124565T3 (en) | 2015-02-09 |
| TW200845991A (en) | 2008-12-01 |
| WO2008089052A2 (en) | 2008-07-24 |
| HRP20150119T1 (hr) | 2015-05-08 |
| ES2528745T3 (es) | 2015-02-12 |
| AU2008206441A1 (en) | 2008-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064878A1 (es) | Compuesto heteroaromatico de glicina n-sustituido con pirididazin-3-ona, su uso para fabricar un medicamento para el tratamiento de la anemia, composicion farmaceutica que lo comprende y proceso para preparar dicho compuesto. | |
| AR061570A1 (es) | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto | |
| CU20160030A7 (es) | Compuestos éteres de arilo yútiles para tratar cancer de célula renal | |
| PE20191078A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina utiles en el tratamiento del cancer | |
| MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AR056785A1 (es) | COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS | |
| AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
| CO6761374A2 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR126912A1 (es) | Compuestos de 6-aminopirazolopirimidina y su uso médico | |
| DOP2013000276A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR078522A1 (es) | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis | |
| MA45223B1 (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AR074870A1 (es) | Derivados de pirazolo (1,5-a ) piridina | |
| NZ626314A (en) | 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections | |
| MA42230B1 (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| AR084935A1 (es) | Derivados de tipo azaindazol o diazaindazol como medicamentos | |
| PE20091972A1 (es) | Compuestos heterociclicos como inhibidores del factor ixa | |
| BR112014025564A8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| TW200800945A (en) | Macrocylic inhibitors of hepatitis c virus | |
| AR061663A1 (es) | Procesos para la preparacion de inhibidores de iv dpp. composiciones farmaceuticas y compuestos relacionados. | |
| BR112015015812A2 (pt) | derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor | |
| PE20160194A1 (es) | Composiciones y metodos para tratar anemia | |
| AR076645A1 (es) | Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |